Yunpeng Yang
Overview
Explore the profile of Yunpeng Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
3865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al.
Nat Med
. 2025 Mar;
PMID: 40082695
Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a...
2.
Yang Y, Yu P, Huang Y, Zhang W, Nie Y, Gao C
Microb Cell Fact
. 2025 Mar;
24(1):53.
PMID: 40050843
Background: A variety of probiotics have been utilized as chassis strains and engineered to develop the synthetic probiotics for disease treatment. Among these probiotics, Lactobacilli, which are generally viewed as...
3.
Guo L, Xu L, Nie Y, Liu L, Liu Z, Yang Y
ISME J
. 2025 Feb;
19(1).
PMID: 39961020
The correlations between gut microbiota and host metabolism have been studied extensively, whereas little relevant work has been done to investigate the impact of gut microbial interactions on host metabolism....
4.
Yang Y, Lu Y, Gao C, Nie Y, Wang H, Huang Y, et al.
Heliyon
. 2025 Feb;
11(2):e41912.
PMID: 39897812
Laboratory non-human primates (NHPs) are commonly subjected to social deprivation in various scientific researches. However, the impact of social deprivation on gut microbiome remains largely unknown. We examined the health...
5.
Liu Z, Ma K, Jia Q, Yang Y, Fan P, Wang Y, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000473.
PMID: 39886162
Objective: Current biomarkers for predicting immunotherapy response in non-small-cell lung cancer (NSCLC) are derived from invasive procedures with limited predictive accuracy. Thus, identifying a non-invasive predictive biomarker would improve patient...
6.
Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, et al.
Lung Cancer
. 2025 Jan;
200:108108.
PMID: 39884222
Background: In the phase 3 ORIENT-11 study, sintilimab plus pemetrexed-platinum provided statistically significant longer overall survival and progression-free survival versus placebo plus pemetrexed-platinum as first-line treatment in patients with locally...
7.
Li Q, Yang Y, Tan M, Xia H, Peng Y, Fu X, et al.
Spectrochim Acta A Mol Biomol Spectrosc
. 2025 Jan;
330:125703.
PMID: 39824010
The detection of pesticide residues in agricultural products is crucial for ensuring food safety. However, traditional methods are often constrained by slow processing speeds and a restricted analytical scope. This...
8.
Zhou H, Zhao Y, Zhang M, Yao J, Leng S, Li X, et al.
J Clin Oncol
. 2024 Dec;
43(9):1123-1136.
PMID: 39621965
Purpose: Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate...
9.
Liu J, Sun D, Xu S, Shen J, Ma W, Zhou H, et al.
Front Immunol
. 2024 Nov;
15:1485703.
PMID: 39569187
Purpose: Currently, chemoimmunotherapy is effective only in a subset of patients with advanced non-squamous non-small cell lung cancer. Robust biomarkers for predicting the efficacy of chemoimmunotherapy would be useful to...
10.
Zhao S, Zhou H, Yang N, Wang Z, Jin W, Ma Y, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39551469
Introduction: Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy,...